Cantor Fitzgerald reaffirmed their hold rating on shares of Integra Lifesciences (NASDAQ:IART) in a report published on Thursday, February 21st. Cantor Fitzgerald currently has a $50.00 price objective on the life sciences company’s stock.
“We maintain our Neutral rating and 12-month price target of $50 on IART. Although we view IART’s long-range plan as impressive, we believe execution over the next few quarters is critical to restoring investor confidence in the stock. We think it is appropriate to stay on the sidelines at this time, but we might become more positive on the stock if the company were to execute on its integration and salesforce restructuring goals. We think IART is fairly valued at current levels, appropriately balancing the long-term opportunities with the risk of near-term disruption from the Codman acquisition and the changes to the OTT sales channel structure.”,” the firm’s analyst wrote.
A number of other equities research analysts have also recently weighed in on IART. Oppenheimer reaffirmed a buy rating and set a $70.00 price target on shares of Integra Lifesciences in a report on Wednesday, October 31st. Wells Fargo & Co lowered their price objective on shares of Integra Lifesciences from $61.00 to $55.00 and set a market perform rating on the stock in a research note on Thursday, November 1st. JMP Securities lowered their price objective on shares of Integra Lifesciences from $66.00 to $62.00 and set a market outperform rating on the stock in a research note on Friday, November 2nd. Citigroup decreased their price target on shares of Integra Lifesciences from $66.00 to $60.00 and set a neutral rating on the stock in a research report on Friday, November 2nd. Finally, Zacks Investment Research restated a sell rating on shares of Integra Lifesciences in a research report on Tuesday, November 13th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $60.67.
NASDAQ IART traded down $0.13 during trading hours on Thursday, reaching $56.01. The company’s stock had a trading volume of 822,287 shares, compared to its average volume of 488,574. The company has a quick ratio of 1.88, a current ratio of 2.95 and a debt-to-equity ratio of 0.97. Integra Lifesciences has a 52 week low of $42.14 and a 52 week high of $67.50. The stock has a market capitalization of $4.78 billion, a P/E ratio of 23.14, a P/E/G ratio of 1.63 and a beta of 0.96.
Integra Lifesciences (NASDAQ:IART) last issued its earnings results on Thursday, February 21st. The life sciences company reported $0.65 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.03. The firm had revenue of $383.30 million for the quarter, compared to analysts’ expectations of $382.33 million. Integra Lifesciences had a net margin of 4.13% and a return on equity of 16.02%. Integra Lifesciences’s revenue was up 4.0% on a year-over-year basis. During the same quarter last year, the company posted $0.64 earnings per share. As a group, equities research analysts expect that Integra Lifesciences will post 2.68 earnings per share for the current year.
In related news, major shareholder Richard E. Caruso sold 30,128 shares of Integra Lifesciences stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $56.06, for a total value of $1,688,975.68. Following the completion of the sale, the insider now owns 143,384 shares of the company’s stock, valued at approximately $8,038,107.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.10% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in IART. Bank of New York Mellon Corp raised its holdings in Integra Lifesciences by 2.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 744,153 shares of the life sciences company’s stock worth $47,931,000 after acquiring an additional 17,431 shares during the period. Oakbrook Investments LLC bought a new stake in Integra Lifesciences in the third quarter valued at about $642,000. Xact Kapitalforvaltning AB increased its stake in Integra Lifesciences by 43.5% in the third quarter. Xact Kapitalforvaltning AB now owns 13,202 shares of the life sciences company’s stock valued at $870,000 after acquiring an additional 4,000 shares during the period. Massachusetts Financial Services Co. MA increased its stake in Integra Lifesciences by 7.3% in the third quarter. Massachusetts Financial Services Co. MA now owns 157,264 shares of the life sciences company’s stock valued at $10,359,000 after acquiring an additional 10,705 shares during the period. Finally, First Trust Advisors LP increased its stake in Integra Lifesciences by 472.3% in the third quarter. First Trust Advisors LP now owns 389,720 shares of the life sciences company’s stock valued at $25,671,000 after acquiring an additional 321,619 shares during the period. Hedge funds and other institutional investors own 83.11% of the company’s stock.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
See Also: How Do You Make Money With Penny Stocks?
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.